Endothelin-1

1. Overview

Endothelin-1 (ET-1) is an endogenous 21-amino-acid vasoactive peptide with the sequence Cys-Ser-Cys-Ser-Ser-Leu-Met-Asp-Lys-Glu-Cys-Val-Tyr-Phe-Cys-His-Leu-Asp-Ile-Ile-Trp (molecular weight 2491.9 Da, molecular formula C109H159N25O32S5) [1][5]. It was discovered in 1988 by Masashi Yanagisawa and colleagues at the University of Tsukuba, Japan, who isolated it from the culture supernatant of porcine aortic endothelial cells and published their landmark findings in Nature on March 31, 1988 [1][9]. That paper remains one of the most highly cited in cardiovascular biology, as it identified what is still recognized as the most potent endogenous vasoconstrictor known -- approximately 10-fold more potent than angiotensin II on a molar basis and with effects lasting hours rather than minutes.

ET-1 is the predominant isoform of the three-member endothelin family (ET-1, ET-2, ET-3), which are encoded by separate genes on different chromosomes [16]. The EDN1 gene encoding ET-1 is located on chromosome 6p23-p24 and produces a 212-amino-acid preproendothelin-1 precursor [22]. Through a two-step proteolytic cascade, this precursor is first processed by furin-like proprotein convertases to yield the 38-amino-acid inactive intermediate Big ET-1, which is then cleaved by endothelin-converting enzymes (ECE-1, ECE-2) at the Trp21-Val22 bond to generate mature, biologically active ET-1 [5][9]. This unusual biosynthetic processing was recognized in the original 1988 paper as a novel mechanism for generating a bioactive peptide.

Structurally, ET-1 contains two intramolecular disulfide bonds (Cys1-Cys15 and Cys3-Cys11) that form a bicyclic ring structure at the N-terminus, connected to a linear hydrophobic C-terminal tail essential for receptor binding and biological activity [5][17]. This structural motif is shared with the sarafotoxins, a family of snake venom peptides from Atractaspis engaddensis, suggesting an ancient evolutionary origin.

The discovery of ET-1 and subsequent elucidation of the endothelin system led directly to the development of endothelin receptor antagonists (ERAs) -- bosentan, ambrisentan, and macitentan -- which have transformed the treatment of pulmonary arterial hypertension (PAH) and represent one of the most successful examples of translational cardiovascular medicine from bench to bedside [9].

Molecular Weight

2491.9 Da

Molecular Formula

C109H159N25O32S5

Sequence

CSCSSLMDKECVYFCHLDIIW (21 amino acids)

Disulfide Bonds

2 (Cys1-Cys15, Cys3-Cys11)

Gene

EDN1 (chromosome 6p23-p24)

Precursor

212-aa preproET-1, cleaved to 38-aa Big ET-1, then to 21-aa ET-1 by ECE

Primary Receptors

ETA (vasoconstriction) and ETB (clearance/vasodilation), both GPCRs

Half-life

4-7 minutes (plasma); tissue effects persist much longer

Discovery

Yanagisawa et al., Nature 1988

FDA-Approved Antagonists

Bosentan (2001), ambrisentan (2007), macitentan (2013), atrasentan (2025, IgA nephropathy)

2. Mechanism of Action

Receptor Signaling

ET-1 exerts its biological effects through two G protein-coupled receptors: the endothelin A receptor (ETA) and the endothelin B receptor (ETB) [5][8][17].

ETA receptor signaling: The ETA receptor is predominantly expressed on vascular smooth muscle cells, cardiomyocytes, and fibroblasts. It binds ET-1 and ET-2 with high affinity but has markedly lower affinity for ET-3 (binding order: ET-1 greater than or equal to ET-2, both much greater than ET-3) [5][16]. Upon ligand binding, ETA couples primarily to Gq/11 proteins, activating phospholipase C-beta (PLC-beta), which hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers rapid calcium release from the sarcoplasmic reticulum, while DAG activates protein kinase C (PKC). The resulting intracellular calcium surge drives vascular smooth muscle contraction, the hallmark vasoconstrictive response [7][17]. Additionally, ETA activates extracellular calcium influx through L-type voltage-gated calcium channels and transient receptor potential canonical (TRPC) channels, particularly TRPC3, sustaining the contractile response [7]. ETA also couples to G12/13 proteins, activating RhoA/Rho kinase pathways that enhance calcium sensitization of the contractile apparatus.

ETB receptor signaling: The ETB receptor is expressed on endothelial cells, vascular smooth muscle cells, and various other cell types. It binds all three endothelin isoforms with equal affinity [5][16]. On endothelial cells, ETB activation stimulates nitric oxide synthase (eNOS) and prostacyclin production, promoting vasodilation -- a counterbalancing effect to ETA-mediated vasoconstriction. ETB on endothelial cells also functions as a clearance receptor, internalizing and removing circulating ET-1, thereby limiting its vasoconstrictive duration. The lung, which receives the entire cardiac output, clears approximately 50% of circulating ET-1 in a single pass via ETB-mediated uptake [5][8]. However, ETB receptors on vascular smooth muscle can also mediate vasoconstriction through the same Gq/calcium pathway as ETA, particularly in certain vascular beds.

Additional signaling pathways: Beyond the canonical Gq pathway, both receptors activate mitogen-activated protein kinase (MAPK) cascades (ERK1/2, p38 MAPK, JNK), phosphatidylinositol 3-kinase (PI3K)/Akt signaling, and reactive oxygen species generation. These pathways drive the mitogenic, pro-fibrotic, and pro-inflammatory effects of ET-1 that extend well beyond acute vasoconstriction [5][17].

Vasoconstrictor Potency

ET-1 produces the most sustained and potent vasoconstriction of any known endogenous substance. Unlike most vasoconstrictors whose effects last seconds to minutes, ET-1-induced contraction can persist for hours after washout, reflecting tight binding kinetics and sustained intracellular signaling. The EC50 for vasoconstriction is in the picomolar to low nanomolar range, and normal plasma concentrations of 1-5 pg/mL are sufficient to exert tonic vasomotor effects [5][9][11].

3. Biosynthesis and Regulation

ET-1 is synthesized primarily by vascular endothelial cells, though production also occurs in vascular smooth muscle cells, cardiomyocytes, macrophages, renal epithelial cells, neurons, and certain tumor cells [5][22]. The biosynthetic pathway proceeds through three steps:

1. Transcription and translation: The EDN1 gene on chromosome 6p23-p24 produces a 2.8 kb mRNA encoding the 212-amino-acid preproendothelin-1. Transcription is tightly regulated and constitutes the primary control point for ET-1 production [22].

2. Proprotein processing: A signal peptide targets preproET-1 to the secretory pathway, where furin-like proprotein convertases cleave it to generate the 38-amino-acid Big ET-1, which has minimal biological activity (approximately 1% of mature ET-1 potency) [5][9].

3. Endothelin-converting enzyme (ECE) cleavage: ECE-1 (the predominant isoform) and ECE-2 are zinc metalloproteases that cleave Big ET-1 at the Trp21-Val22 bond, generating mature ET-1. This final step occurs both intracellularly (within secretory vesicles) and at the cell surface [5].

Transcriptional regulation: ET-1 gene expression is induced by hypoxia, shear stress, thrombin, angiotensin II, transforming growth factor-beta, inflammatory cytokines (IL-1, TNF-alpha), insulin, and oxidized LDL. It is suppressed by nitric oxide, prostacyclin, natriuretic peptides, and high laminar shear stress [5][22]. This regulatory profile places ET-1 at a convergence point of multiple pathophysiological pathways.

ET-1 is released predominantly abluminally (toward the underlying smooth muscle) rather than into the blood, functioning as a paracrine/autocrine mediator. Plasma levels represent only a fraction of total ET-1 production and are maintained at low levels through rapid pulmonary clearance via ETB receptors and enzymatic degradation by neutral endopeptidase 24.11 [5][11].

4. The Endothelin Isoform Family

The endothelin family comprises three structurally related 21-amino-acid isopeptides -- ET-1, ET-2, and ET-3 -- each encoded by separate genes on distinct chromosomes [16].

ET-1 (EDN1, chromosome 6p23-p24) is the predominant cardiovascular isoform, produced primarily by endothelial cells. It acts through both ETA and ETB receptors and is the principal mediator of endothelin-related vascular pathology.

ET-2 (EDN2, chromosome 1p34) differs from ET-1 by only two amino acids (Ser6 replaced by Trp and Asn4 replaced by Ser). It shares similar ETA and ETB binding affinity with ET-1 and is expressed in the kidney, intestine, ovary, and heart. ET-2 plays a role in ovarian physiology and ovulation and is implicated in certain inflammatory and immune processes [5][16].

ET-3 (EDN3, chromosome 20q13.2-q13.3) differs from ET-1 at six positions within the N-terminal loop region. This structural divergence confers markedly reduced ETA affinity (100-fold lower than ET-1) while maintaining equal ETB binding, making ET-3 functionally selective for the ETB receptor. ET-3 is important in neural crest development -- mutations in ET-3 or ETB cause Hirschsprung disease (aganglionic megacolon) and Waardenburg-Shah syndrome due to defective enteric neuron and melanocyte development [5][16][17].

5. Researched Applications

Pulmonary Arterial Hypertension

Evidence level: Strong (multiple Phase III RCTs; three FDA-approved ERAs)

PAH is the condition for which the endothelin system has yielded the greatest clinical success. ET-1 levels are elevated in both plasma and lung tissue of PAH patients, and the degree of elevation correlates with disease severity and prognosis [2][4][6]. ET-1 drives the characteristic features of PAH -- sustained vasoconstriction, vascular smooth muscle proliferation, and adventitial fibrosis of pulmonary arteries -- primarily through ETA receptor activation.

Three endothelin receptor antagonists have been approved by the FDA for PAH treatment, each validated in landmark clinical trials:

Bosentan (dual ETA/ETB antagonist) was the first oral ERA approved (2001). The pivotal BREATHE-1 trial randomized 213 WHO class III-IV PAH patients to bosentan (125 or 250 mg twice daily) or placebo for 16 weeks [2]. Bosentan improved 6-minute walk distance by 44 meters versus placebo, improved WHO functional class, and delayed time to clinical worsening. An earlier proof-of-concept study by Channick et al. in 32 patients had shown a treatment effect of 76 meters [10].

Ambrisentan (selective ETA antagonist) was approved in 2007 based on the concurrent ARIES-1 and ARIES-2 trials in 394 PAH patients [3]. Ambrisentan improved 6-minute walk distance by 31-59 meters across dose groups (2.5-10 mg once daily). Notably, no patients in either trial developed aminotransferase elevations greater than three times the upper limit of normal, representing a significant safety advantage over bosentan.

Macitentan (dual ETA/ETB antagonist with tissue-targeting properties) was approved in 2013 based on the landmark SERAPHIN trial [4]. This was the largest (742 patients) and longest (event-driven, median follow-up 115 weeks) PAH trial ever conducted and the first to use a morbidity/mortality composite as its primary endpoint. Macitentan 10 mg reduced the risk of the composite endpoint by 45% versus placebo (hazard ratio 0.55, p value of 0.001). The composite included PAH worsening, initiation of intravenous/subcutaneous prostanoids, lung transplantation, atrial septostomy, or death.

ERAs are now established as cornerstone therapy in PAH treatment algorithms, typically used in combination with phosphodiesterase-5 inhibitors and/or prostacyclin pathway agents as part of a goal-oriented, multi-pathway treatment strategy [6].

Cardiac Hypertrophy and Heart Failure

Evidence level: Moderate (strong preclinical evidence; clinical trials in heart failure disappointing)

ET-1 is a potent stimulus for cardiomyocyte hypertrophy, acting through ETA receptors to activate calcineurin-NFAT, MAPK, and RhoA/ROCK signaling pathways. Myocardial ET-1 expression is upregulated in pressure overload, ischemia-reperfusion injury, and heart failure, where it contributes to adverse remodeling, fibrosis, and contractile dysfunction [5][9][11]. Despite compelling preclinical rationale, clinical trials of ERAs in heart failure (including the ENABLE trials with bosentan and the EARTH trial with darusentan) failed to demonstrate clinical benefit, possibly because ETB-mediated clearance and vasodilatory mechanisms are also blocked by dual antagonists, and the hemodynamic effects of ERAs include fluid retention [9].

Chronic Kidney Disease

Evidence level: Moderate (clinical trials ongoing)

The renal endothelin system is one of the most actively investigated therapeutic targets in nephrology. ET-1 is produced by endothelial cells, mesangial cells, and podocytes in the kidney and acts through ETA receptors to promote glomerular vasoconstriction, sodium retention, mesangial cell proliferation, podocyte injury, and tubulointerstitial fibrosis [11][15]. In chronic kidney disease, ET-1 drives reactive oxygen species production, loss of glomerular barrier proteins, and progressive fibrosis. The selective ETA antagonist atrasentan has shown promise in reducing proteinuria in diabetic kidney disease in the SONAR trial, representing a potential new ERA indication beyond PAH [6][15].

Subarachnoid Hemorrhage and Cerebral Vasospasm

Evidence level: Moderate (Phase II/III clinical trials)

Cerebral vasospasm following aneurysmal subarachnoid hemorrhage (aSAH) is a major cause of morbidity and mortality. ET-1 levels in cerebrospinal fluid rise dramatically after SAH and correlate temporally with the development and severity of vasospasm, typically peaking at days 4-8 post-hemorrhage [13][14]. ET-1 acts through ETA receptors on cerebral arterial smooth muscle, increasing calcium influx through TRPC1, TRPC4, and L-type channels to produce sustained contraction [13].

Clazosentan, a selective ETA antagonist, was developed specifically for this indication. The CONSCIOUS-1 Phase II trial in 413 aSAH patients showed dose-dependent reduction in moderate-to-severe angiographic vasospasm, with the 15 mg/h dose reducing vasospasm by 65% relative to placebo [14]. However, the Phase III CONSCIOUS-2 trial in 768 patients undergoing surgical clipping failed to demonstrate significant reduction in the composite morbidity/mortality endpoint, despite reducing vasospasm [21]. This dissociation between angiographic and clinical outcomes remains a subject of active investigation.

Cancer

Evidence level: Preliminary (preclinical and early clinical)

ET-1 has emerged as a multifunctional mediator in cancer biology, with overexpression documented in ovarian, prostate, breast, colorectal, bladder, and lung carcinomas [12][19]. The oncogenic actions of ET-1 include:

• Proliferation and survival: ETA activation drives mitogenic signaling through MAPK and PI3K/Akt pathways and inhibits apoptosis through Bcl-2 upregulation [12][19].
• Angiogenesis: ET-1 promotes neovascularization both directly (ETB-mediated endothelial cell proliferation and migration) and indirectly (ETA-mediated induction of VEGF through HIF-1alpha stabilization) [12][19][20].
• Invasion and metastasis: ET-1 upregulates matrix metalloproteinases (MMP-2, MMP-9) while downregulating tissue inhibitors of metalloproteinases (TIMP-1, TIMP-2), facilitating extracellular matrix degradation and tumor invasion [12].
• Bone metastasis: In prostate cancer, ET-1 promotes osteoblastic bone metastases through ETA receptor signaling, and the selective ETA antagonist zibotentan (ZD4054) was evaluated in Phase III trials for castration-resistant prostate cancer, though it ultimately did not meet its primary endpoint [19].
• Immune evasion: ETB receptor expression on tumor vasculature has been linked to suppression of T-cell homing and immune surveillance [19].

The clinical translation of ET receptor antagonism in oncology remains an active area of investigation, though no ERA has achieved regulatory approval for a cancer indication.

IgA Nephropathy (Strong Evidence -- FDA Approved 2025)

In April 2025, the FDA granted accelerated approval to atrasentan (Vanrafia, Novartis) for the reduction of proteinuria in adults with primary IgA nephropathy (IgAN) at risk of rapid disease progression (generally UPCR of 1.5 g/g or greater). This represents the first FDA-approved selective ETA receptor antagonist for a renal indication and a landmark expansion of the endothelin therapeutic landscape beyond PAH. The approval was based on the Phase 3 ALIGN trial, which demonstrated significant proteinuria reduction with atrasentan compared to placebo. Traditional approval will depend on ongoing eGFR decline data expected in 2026. Atrasentan is dosed at 0.75 mg orally once daily and has a manageable safety profile with fluid retention as the primary concern.

6. Clinical Evidence Summary

7. Dosing in Research

The following table summarizes dosing regimens of endothelin receptor antagonists used in landmark clinical trials. These agents are prescription medications approved specifically for pulmonary arterial hypertension (except where noted) and must be prescribed and monitored by specialists.

8. Safety and Side Effects

Endothelin Receptor Antagonist Safety Profiles

A comprehensive meta-analysis of 4,894 patients across 24 randomized, double-blind, placebo-controlled trials established the distinct adverse effect profiles of the three approved ERAs [18]:

Bosentan: The principal safety concern is dose-dependent hepatotoxicity, with a relative risk of 2.93 for elevated liver transaminases compared with placebo. The mechanism involves inhibition of the canalicular bile salt export pump (BSEP), leading to intrahepatic cholestasis. Monthly liver function monitoring is mandatory, and approximately 10-14% of patients develop aminotransferase elevations exceeding three times the upper limit of normal. Bosentan is available only through a restricted distribution program (REMS) requiring liver function monitoring [6][18].

Ambrisentan: As a selective ETA antagonist, ambrisentan has a distinctly different hepatic safety profile. The FDA removed its liver injury warning in 2015 after post-marketing data confirmed no excess hepatotoxicity risk. The primary adverse effect is peripheral edema (RR 1.62 versus placebo), likely related to fluid retention. Headache and nasal congestion are common [3][18].

Macitentan: Despite being a dual antagonist like bosentan, macitentan has not been associated with significant hepatotoxicity, possibly due to its tissue-targeting pharmacokinetic profile with sustained receptor occupancy. The primary safety signal is anemia (RR 3.42 versus placebo), with a dose-dependent decrease in hemoglobin of approximately 1 g/dL attributed to hemodilution and possibly a direct effect on erythropoiesis [4][18].

Class-Wide Safety Considerations

Teratogenicity: All ERAs are pregnancy category X and absolutely contraindicated in pregnancy due to craniofacial, cardiovascular, and mandibular malformations observed in animal studies. Female patients of childbearing potential must use two reliable forms of contraception, and monthly pregnancy testing is required [6][18].

Fluid retention: ERAs can cause fluid retention and peripheral edema, which may worsen right heart failure in advanced PAH patients. This effect contributed to the failure of ERA trials in systolic heart failure [9].

Drug interactions: Bosentan is a moderate inducer of CYP3A4 and CYP2C9 and can reduce the efficacy of hormonal contraceptives, warfarin, sildenafil, and other co-administered medications. Ambrisentan and macitentan have fewer drug interaction concerns [6].

Hemoglobin decrease: All ERAs can cause a mild decrease in hemoglobin, likely through hemodilution related to fluid retention, though this is most clinically significant with macitentan [18].

9. Pharmacokinetics

Endogenous ET-1 Kinetics

ET-1 is not administered as a therapeutic agent; rather, it is an endogenous paracrine/autocrine mediator whose pharmacokinetics describe its physiological production, distribution, and clearance [5][9][11].

Plasma half-life: The circulating half-life of ET-1 is extremely short, approximately 1-2 minutes, reflecting rapid clearance primarily by ETB receptor-mediated internalization in the pulmonary vasculature [5][8]. The lung clears approximately 50% of circulating ET-1 in a single pass through ETB-mediated uptake and lysosomal degradation. Additional clearance occurs via neutral endopeptidase 24.11 (neprilysin) on endothelial cell surfaces.

Paracrine signaling: Despite the very short plasma half-life, the biological effects of ET-1 at the tissue level persist for hours. This discrepancy is explained by the paracrine nature of ET-1 signaling: the peptide is secreted predominantly abluminally (toward the underlying smooth muscle) rather than into the bloodstream [5][11]. Tissue concentrations at the site of production are estimated to be 100-fold or higher than plasma levels. Once bound to ETA receptors on vascular smooth muscle, ET-1 exhibits extremely slow receptor dissociation kinetics, with receptor-bound ET-1 producing sustained intracellular calcium signaling and contraction lasting 2-4 hours after a single exposure [7][17].

Plasma concentrations: Normal circulating ET-1 levels are 1-5 pg/mL (0.4-2.0 pmol/L), reflecting the net balance between production (predominantly endothelial) and clearance [5][9]. In pathological states, levels rise modestly (rarely exceeding 20-30 pg/mL even in severe PAH), underscoring that plasma measurements capture only a small fraction of total ET-1 activity, which occurs primarily in the paracrine compartment.

Big ET-1 as a pharmacokinetic surrogate: Because mature ET-1 has such a short half-life, the inactive precursor Big ET-1 (half-life approximately 15-20 minutes) is often measured as a more reliable biomarker of total ET-1 production. Big ET-1 levels correlate with disease severity in PAH, heart failure, and acute coronary syndromes [5].

ERA Pharmacokinetics

The three FDA-approved endothelin receptor antagonists have distinct pharmacokinetic profiles that influence their clinical use [6][18]:

| Parameter | Bosentan | Ambrisentan | Macitentan | |-----------|----------|-------------|------------| | Receptor selectivity | Dual (ETA/ETB) | Selective ETA | Dual (ETA/ETB), tissue-targeting | | Oral bioavailability | ~50% | High (~90%) | ~74% | | Time to Cmax | 3-5 hours | ~2 hours | ~8 hours | | Terminal half-life | ~5 hours | ~15 hours | ~16 hours (parent); ~48 hours (active metabolite ACT-132577) | | Protein binding | greater than 98% | 99% | greater than 99% | | Metabolism | CYP3A4 and CYP2C9 | Glucuronidation (UGT), minor CYP3A4 | CYP3A4 (major), CYP2C8 | | Active metabolites | Ro 48-5033 (10-20% potency) | None significant | ACT-132577 (equipotent, t1/2 ~48 h) | | Steady-state time | 3-5 days | 4-5 days | ~5 days (parent); ~10 days (metabolite) | | CYP enzyme effects | Moderate inducer of CYP3A4/2C9 | Minimal | Minimal |

Macitentan's tissue-targeting properties are a key pharmacokinetic distinction [4][6]. Unlike bosentan, which achieves relatively transient receptor occupancy due to its short half-life, macitentan and its active metabolite ACT-132577 (half-life approximately 48 hours) provide sustained, near-continuous receptor blockade. This prolonged tissue-level receptor occupancy is hypothesized to contribute to macitentan's superiority in the SERAPHIN morbidity/mortality trial, as it ensures uninterrupted inhibition of ET-1-driven vascular remodeling in the pulmonary vasculature.

Bosentan's enzyme induction creates clinically significant drug interactions: it reduces plasma levels of sildenafil (by approximately 50%), hormonal contraceptives, and warfarin through CYP3A4/2C9 induction [6][18]. This necessitates dose adjustments and alternative contraception methods.

10. Dose-Response Relationships

ERA Dose-Response in PAH

The dose-response relationships for ERAs have been characterized across multiple Phase III trials [2][3][4][10]:

Bosentan:

• 62.5 mg twice daily (starting dose for 4 weeks): Submaximal efficacy but reduced hepatotoxicity risk during dose titration
• 125 mg twice daily: Optimal therapeutic dose; BREATHE-1 showed 44-meter improvement in 6-minute walk distance (6MWD) versus placebo [2]
• 250 mg twice daily: No additional efficacy over 125 mg in BREATHE-1, but increased hepatotoxicity risk (14% vs. 6% aminotransferase elevation), establishing 125 mg twice daily as the recommended maintenance dose [2]

Ambrisentan:

• 2.5 mg once daily: Modest improvement in 6MWD (ARIES-2: +32 meters) [3]
• 5 mg once daily: Significant improvement (ARIES-1: +31 meters; ARIES-2: +51 meters) [3]
• 10 mg once daily: Maximal efficacy (ARIES-1: +51 meters), with a dose-response trend favoring higher doses [3]
• The dose-response curve for ambrisentan is relatively flat between 5 and 10 mg, suggesting near-maximal ETA receptor occupancy at 5 mg in most patients

Macitentan:

• 3 mg once daily: 30% reduction in morbidity/mortality composite (HR 0.70 vs. placebo) in SERAPHIN [4]
• 10 mg once daily: 45% reduction (HR 0.55 vs. placebo), significantly superior to the 3 mg dose, establishing 10 mg as the recommended therapeutic dose [4]
• The steeper dose-response for macitentan compared with bosentan likely reflects the importance of sustained, high-level receptor occupancy for preventing disease progression rather than merely producing acute hemodynamic improvement

Clazosentan (cerebral vasospasm):

• 1 mg/h IV: Minimal reduction in angiographic vasospasm after SAH [14]
• 5 mg/h IV: Moderate reduction (~38% relative reduction)
• 15 mg/h IV: Maximal reduction (~65% relative reduction in moderate-to-severe vasospasm)
• The dose-response was clear for angiographic vasospasm but did not translate into proportional clinical outcome improvement in CONSCIOUS-2 [14][21]

ET-1 Concentration-Effect Relationships

As an endogenous mediator, ET-1 demonstrates potent concentration-effect relationships in vascular tissue:

• EC50 for vasoconstriction: Picomolar to low nanomolar range (approximately 0.1-1 nM depending on vascular bed) [5][9]
• Maximal vasoconstriction: Achieved at approximately 10-100 nM
• ET-1 is 10-fold more potent than angiotensin II on a molar basis and produces contraction lasting hours rather than minutes due to quasi-irreversible ETA receptor binding
• Concentration in plasma vs. tissue: Plasma levels (1-5 pg/mL, ~0.4-2 pmol/L) are vastly below the EC50, confirming that vasoactive effects are mediated by locally produced ET-1 in the paracrine compartment, not by circulating peptide [5][11]

11. Comparative Effectiveness

ERAs vs. PDE5 Inhibitors for PAH

PDE5 inhibitors (sildenafil, tadalafil) represent the other major oral drug class targeting the vasoconstriction/vasodilation imbalance in PAH. No large head-to-head trial has compared ERAs directly with PDE5 inhibitors, but indirect comparisons and combination data inform clinical decision-making [6]:

| Parameter | ERAs (bosentan/ambrisentan/macitentan) | PDE5 Inhibitors (sildenafil/tadalafil) | |-----------|----------------------------------------|----------------------------------------| | Mechanism | Block ET-1-mediated vasoconstriction/remodeling | Enhance NO/cGMP-mediated vasodilation | | 6MWD improvement | 30-60 meters | 40-50 meters (SUPER-1 sildenafil: +45 m) | | Morbidity/mortality data | SERAPHIN: 45% reduction (macitentan 10 mg) | No dedicated morbidity/mortality trial | | Anti-remodeling effects | Strong (inhibit smooth muscle proliferation, fibrosis) | Moderate (cGMP-mediated anti-proliferative) | | Hepatotoxicity | Bosentan yes; ambrisentan, macitentan no | No | | Teratogenicity | Class-wide (pregnancy category X) | Not teratogenic | | Drug interactions | Bosentan: significant (CYP inducer) | Sildenafil: moderate (CYP3A4 substrate) |

ERAs vs. Prostacyclin Pathway Agents

Prostacyclin analogs (epoprostenol, treprostinil, iloprost) and the prostacyclin receptor agonist selexipag target the third major pathogenic pathway in PAH [6]:

• Epoprostenol IV remains the only PAH therapy with a demonstrated survival benefit in a single randomized trial (Barst et al. 1996)
• ERAs are preferred as initial oral therapy due to ease of administration, while parenteral prostanoids are reserved for WHO FC III-IV disease or patients failing oral combination therapy
• AMBITION trial established initial combination therapy with ambrisentan plus tadalafil as superior to either monotherapy, reducing clinical failure by 50% versus monotherapy

ERAs vs. Riociguat

Riociguat (soluble guanylate cyclase stimulator) represents a newer approach that enhances NO-cGMP signaling independently of endogenous NO availability [6]:

• Riociguat is the only approved medical therapy for chronic thromboembolic pulmonary hypertension (CTEPH) as well as PAH
• In PAH, riociguat (PATENT-1 trial) improved 6MWD by 30 meters versus placebo
• Contraindicated with PDE5 inhibitors (hypotension risk), but can be combined with ERAs
• No head-to-head comparison with ERAs in PAH; riociguat occupies a unique niche in CTEPH

Modern Combination Strategies

Current PAH treatment algorithms employ goal-oriented combination therapy targeting multiple pathogenic pathways simultaneously [6]:

• Low/intermediate risk: Initial dual oral therapy (ERA + PDE5i, as in AMBITION)
• High risk at diagnosis: Upfront triple therapy including IV/SC prostanoid (ERA + PDE5i + epoprostenol/treprostinil)
• ERAs serve as the cornerstone of virtually all combination regimens, reflecting the centrality of the endothelin pathway in PAH pathogenesis

12. Enhanced Safety Profile

ERA Class-Wide Safety Monitoring

All ERAs require specific safety monitoring reflecting both class-wide and agent-specific toxicities [6][18]:

Pregnancy prevention (class-wide):

• All ERAs are absolutely contraindicated in pregnancy (category X)
• Two reliable forms of contraception are mandatory for female patients of childbearing potential
• Monthly pregnancy testing is required
• Bosentan reduces hormonal contraceptive efficacy through CYP induction, necessitating non-hormonal backup methods

Hepatic monitoring (bosentan-specific):

• Monthly liver function tests are mandatory with bosentan (REMS program)
• Aminotransferase elevations greater than 3x ULN occur in 10-14% of patients [18]
• Mechanism: inhibition of the bile salt export pump (BSEP) causing intrahepatic cholestasis
• Hepatotoxicity is dose-dependent, generally reversible upon dose reduction or discontinuation
• Ambrisentan and macitentan do not require routine hepatic monitoring (FDA removed liver warning for ambrisentan in 2015)

Hematologic monitoring (macitentan):

• Hemoglobin decrease of approximately 1 g/dL is expected with macitentan [4][18]
• Anemia risk: RR 3.42 versus placebo (meta-analysis) [18]
• Mechanism: likely hemodilution combined with a possible direct erythropoietic effect
• Complete blood count monitoring is recommended at baseline, 1 month, and periodically thereafter

Agent-Specific Safety Profiles

Bosentan safety profile (meta-analysis of 4,894 patients) [18]:

• Hepatotoxicity: RR 2.93 (principal safety concern)
• Peripheral edema: RR 1.56
• Headache: common, usually self-limiting
• Anemia: mild, less pronounced than macitentan
• No significant QTc prolongation

Ambrisentan safety profile [3][18]:

• Peripheral edema: RR 1.62 (principal adverse effect)
• Nasal congestion: 6-10%
• No hepatotoxicity signal (liver warning removed by FDA in 2015)
• Contraindicated in idiopathic pulmonary fibrosis (ARTEMIS-IPF trial showed harm)

Macitentan safety profile [4][18]:

• Anemia: RR 3.42 (principal safety signal)
• Upper respiratory tract infection: increased frequency
• No hepatotoxicity signal despite dual receptor antagonism
• Headache: common but rarely treatment-limiting

Fluid Retention and Heart Failure Risk

ERAs can cause clinically significant fluid retention, which is particularly relevant in PAH patients with right ventricular dysfunction [9][18]:

• Peripheral edema occurs in 5-15% of ERA-treated patients across class
• In the ENABLE trials (bosentan in left heart failure), fluid retention contributed to early worsening events, contributing to trial failure
• Diuretic dose optimization is recommended when initiating ERA therapy in patients with signs of volume overload
• Fluid retention is more pronounced with dual ERAs (bosentan, macitentan) than with selective ETA antagonism (ambrisentan), possibly because ETB blockade eliminates the natriuretic effect of endothelial ETB receptor activation

Long-Term Safety

SERAPHIN provided the most extensive long-term safety data for any ERA, with median follow-up of 115 weeks [4]:

• No new safety signals emerged with prolonged macitentan exposure
• The morbidity/mortality benefit was sustained throughout the treatment period
• Discontinuation rates for adverse events were comparable between macitentan and placebo (13.6% vs. 13.2%)
• These data support the long-term safety of ERA therapy when appropriate monitoring is maintained

13. Endothelin-1 as a Biomarker

Plasma ET-1 levels serve as prognostic biomarkers in several cardiovascular and pulmonary conditions. In PAH, elevated ET-1 correlates with disease severity, hemodynamic impairment, and mortality [5][6]. In heart failure, ET-1 levels rise with increasing NYHA functional class. In acute coronary syndromes, elevated ET-1 predicts adverse outcomes. In aSAH, cerebrospinal fluid ET-1 concentrations predict the development and severity of delayed cerebral vasospasm [13][14]. Big ET-1, the inactive precursor, is also measured as a biomarker because it has a longer half-life than mature ET-1 and better reflects total ET-1 production rather than net secretion after clearance [5].

14. Related Peptides

See also: Angiotensin-(1-7), Adrenomedullin, CGRP (Calcitonin Gene-Related Peptide)

15. References

1. [1] Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. (1988). A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. DOI PubMed
2. [2] Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. (2002). Bosentan therapy for pulmonary arterial hypertension. New England Journal of Medicine. DOI PubMed
3. [3] Galie N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, et al. (2008). Ambrisentan for the treatment of pulmonary arterial hypertension - results of the ARIES study 1 and 2. Circulation. DOI PubMed
4. [4] Pulido T, Adzerikho I, Channick RN, Delcroix M, Galie N, Ghofrani HA, et al. (2013). Macitentan and morbidity and mortality in pulmonary arterial hypertension. New England Journal of Medicine. DOI PubMed
5. [5] Davenport AP, Hyndman KA, Dhaun N, Southan C, Kohan DE, Pollock JS, et al. (2016). Endothelin. Pharmacological Reviews. DOI PubMed
6. [6] Iglarz M, Clozel M. (2020). Endothelin receptor antagonists - status quo and future perspectives for targeted therapy. Journal of Clinical Medicine. DOI PubMed
7. [7] Khimji AK, Bhatt D. (2014). The interdependence of endothelin-1 and calcium. Current Vascular Pharmacology. DOI PubMed
8. [8] Maguire JJ, Davenport AP. (2015). Endothelin receptors and their antagonists. Seminars in Nephrology. DOI PubMed
9. [9] Barton M, Yanagisawa M. (2019). Endothelin - 30 years from discovery to therapy. Hypertension. DOI PubMed
10. [10] Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. (2001). Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension - a randomised placebo-controlled study. Lancet. DOI PubMed
11. [11] Kohan DE, Rossi NF, Inscho EW, Pollock DM. (2011). Regulation of blood pressure and salt homeostasis by endothelin. Physiological Reviews. DOI PubMed
12. [12] Rosano L, Spinella F, Bagnato A. (2008). Endothelin-1 is a multifunctional molecule in cancer. British Journal of Cancer. DOI PubMed
13. [13] Nishida M, Okada Y, Akiyoshi K, Oshiro S, Kakino S, Ono K, et al. (2007). Novel mechanism of endothelin-1-induced vasospasm after subarachnoid hemorrhage. Journal of Neurosurgery. DOI PubMed
14. [14] Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, et al. (2008). Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1). Stroke. DOI PubMed
15. [15] Dhaun N, Goddard J, Webb DJ. (2006). The endothelin system and its antagonism in chronic kidney disease. Journal of the American Society of Nephrology. DOI PubMed
16. [16] Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K, Masaki T. (1989). The human endothelin family - three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proceedings of the National Academy of Sciences. DOI PubMed
17. [17] Kawanabe Y, Nauli SM. (2011). Endothelin. Cellular and Molecular Life Sciences. DOI PubMed
18. [18] Shao D, Park JE, Bhatt DK, Bhatt SR, Bhatt SP. (2017). Clinical adverse effects of endothelin receptor antagonists - insights from meta-analysis of 4894 patients. Journal of the American Heart Association. DOI PubMed
19. [19] Nelson J, Bagnato A, Battistini B, Nisen P. (2003). The endothelin axis - emerging role in cancer. Nature Reviews Cancer. DOI PubMed
20. [20] Salani D, Taraboletti G, Rosano L, Di Castro V, Borsotti P, Gasparini ML, et al. (2000). Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. American Journal of Pathology. DOI PubMed
21. [21] Macdonald RL, Kassell NF, Mayer S, Ruefenacht D, Schmiedek P, Weidauer S, et al. (2011). Clazosentan in patients with aneurysmal subarachnoid haemorrhage (CONSCIOUS-2). Lancet Neurology. DOI PubMed
22. [22] Hynynen MM, Bhatt DK. (2011). Endothelin-1 gene regulation. Vascular Pharmacology. DOI PubMed